UCB builds on relationship with Microsoft with new AI deal; Sanofi partners with German AAV vector biotech
More biotechs are jumping on the AI bandwagon, and you can count UCB as one of them.
The Belgian company inked a “multi-year” deal with Microsoft on Tuesday, gaining access to its computational services, cloud and AI tech. The collaboration builds on work UCB did with Microsoft through the COVID Moonshot project, a crowdsourced initiative to accelerate the development of antiviral candidates.
“It’s one of the experiences that built up to this partnership,” CIO Herman De Prins said in an interview with Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.